Dietary exclusions for established atopic eczema (Review)

Bath-Hextall FJ, Delamere FM, Williams HC

This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2008, Issue 4

http://www.thecochranelibrary.com
# Table of Contents

- **Header** .................................................. 1
- **Abstract** .................................................. 1
- **Plain Language Summary** .............................. 2
- **Background** ................................................ 2
- **Objectives** ............................................... 4
- **Methods** .................................................. 5
- **Results** ................................................... 7
- **Discussion** ................................................ 11
- **Authors' Conclusions** .................................. 12
- **Acknowledgements** ...................................... 13
- **References** ............................................... 16
- **Characteristics of Studies** ............................ 24
- **Data and Analyses** ...................................... 24
  - Analysis 1.1. Comparison 1 Dried soya vs dried egg and cows milk, Outcome 1 activity score at one month. .................................................. 26
  - Analysis 2.1. Comparison 2 eHF vs Amino acid formula, Outcome 1 Severity of atopic eczema at 2-3 months. .................................................. 27
  - Analysis 2.2. Comparison 2 eHF vs Amino acid formula, Outcome 2 Severity of atopic eczema at 6-8 months. .................................................. 27
  - Analysis 3.1. Comparison 3 Egg exclusion vs normal diet, Outcome 1 Number of participants whose body surface area are improved. .................................................. 28
  - Analysis 3.2. Comparison 3 Egg exclusion vs normal diet, Outcome 2 Change in body surface area at 6 weeks. .................................................. 28
  - Analysis 3.3. Comparison 3 Egg exclusion vs normal diet, Outcome 3 Change in severity score - end of treatment. .................................................. 29
  - Analysis 4.1. Comparison 4 Few foods with whey vs normal diet, Outcome 1 Change in day time itch at 6 weeks. .................................................. 29
  - Analysis 4.2. Comparison 4 Few foods with whey vs normal diet, Outcome 2 Change in sleep disturbances at 6 weeks. .................................................. 30
  - Analysis 4.3. Comparison 4 Few foods with whey vs normal diet, Outcome 3 Change in body surface area affected at 6 weeks. .................................................. 30
  - Analysis 4.4. Comparison 4 Few foods with whey vs normal diet, Outcome 4 Change in skin severity score at 6 weeks. .................................................. 31
  - Analysis 5.1. Comparison 5 Few foods with casein vs normal diet, Outcome 1 Change in day time itch at 6 weeks. .................................................. 31
  - Analysis 5.2. Comparison 5 Few foods with casein vs normal diet, Outcome 2 Change in sleep disturbances at 6 weeks. .................................................. 32
  - Analysis 5.3. Comparison 5 Few foods with casein vs normal diet, Outcome 3 Change in body surface area affected at 6 weeks. .................................................. 32
  - Analysis 5.4. Comparison 5 Few foods with casein vs normal diet, Outcome 4 Change in skin severity score at 6 weeks. .................................................. 33
  - Analysis 6.1. Comparison 6 Few foods with whey vs few foods with casein, Outcome 1 Change in day time itch at 6 weeks. .................................................. 33
  - Analysis 6.2. Comparison 6 Few foods with whey vs few foods with casein, Outcome 2 Change in sleep disturbances at 6 weeks. .................................................. 34
  - Analysis 6.3. Comparison 6 Few foods with whey vs few foods with casein, Outcome 3 Change in body surface area affected at 6 weeks. .................................................. 34
  - Analysis 6.4. Comparison 6 Few foods with whey vs few foods with casein, Outcome 4 Change in skin severity score at 6 weeks. .................................................. 35
  - Analysis 7.1. Comparison 7 Elemental diet vs normal diet, Outcome 1 Number of participants whose eczema improved (change in intensity and extension) at 3 weeks. .................................................. 35
  - Analysis 7.2. Comparison 7 Elemental diet vs normal diet, Outcome 2 Numbers who improved for pruritus, sleeplessness and antihistamine consumption at 3 weeks. .................................................. 36
- **Additional Tables** ........................................ 36
- **Appendices** ............................................... 38
- **What's New** ................................................. 43
- **History** .................................................... 43
- **Contributions of Authors** .............................. 43
- **Declarations of Interest** ............................... 43
- **Sources of Support** ...................................... 44
- **Index Terms** ............................................... 44

---

Dietary exclusions for established atopic eczema (Review)  
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dietary exclusions for established atopic eczema

Fiona J Bath-Hextall1, Finola M Delamere2, Hywel C Williams3

1School of Nursing, Faculty of Medicine and Health Science, The University of Nottingham, Nottingham, UK. 2Centre of Evidence-Based Dermatology, Cochrane Skin Group, The University of Nottingham, Nottingham, UK. 3Centre of Evidence-Based Dermatology, The University of Nottingham, Nottingham, UK

Contact address: Fiona J Bath-Hextall, School of Nursing, Faculty of Medicine and Health Science, The University of Nottingham, Room D83, Medical school, Queens medical centre, Nottingham, NG7 2UH, UK. fiona.bath-hextall@nottingham.ac.uk.

Editorial group: Cochrane Skin Group.

Publication status and date: Edited (no change to conclusions), published in Issue 4, 2008.

Review content assessed as up-to-date: 5 November 2007.


Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Atopic eczema (AE) is a non-infective chronic inflammatory skin disease characterised by an itchy red rash.

Objectives

To assess the effects of dietary exclusions for the treatment of established atopic eczema.

Search methods


Selection criteria

People who have atopic eczema as diagnosed by a doctor.

Data collection and analysis

Two independent authors carried out study selection and assessment of methodological quality.

Main results

We found 9 RCTs involving a total of 421 participants of which 6 were studies of egg and milk exclusion (N=288), 1 was a study of few foods (N=85) and 2 were studies of an elemental diet (N=48).

There appears to be no benefit of an egg and milk free diet in unselected participants with atopic eczema. There is also no evidence of benefit in the use of an elemental or few-foods diet in unselected cases of atopic eczema. There may be some benefit in using an egg-free diet in infants with suspected egg allergy who have positive specific IgE to eggs - one study found 51% of the children had a significant improvement in body surface area with the exclusion diet compared to normal diet (RR 1.51, 95% CI 1.07 to 2.11) and...
change in surface area and severity score was significantly improved in the exclusion diet compared to the normal diet at the end of 6 weeks (MD 5.50, 95% CI 0.19 to 10.81) and end of treatment (MD 6.10, 95% CI 0.06 to 12.14).

Methodological difficulties have made it difficult to interpret these studies. Poor concealment of randomisation allocation, lack of blinding and high dropout rates without an intention-to-treat analysis indicates that these studies should be interpreted with great caution.

Authors’ conclusions

There may be some benefit in using an egg-free diet in infants with suspected egg allergy who have positive specific IgE to eggs. Little evidence supports the use of various exclusion diets in unselected people with atopic eczema, but that may be because they were not allergic to those substances in the first place. Lack of any benefit may also be because the studies were too small and poorly reported. Future studies should be appropriately powered focusing on participants with a proven food allergy. In addition a distinction should be made between young children whose food allergies improve with time and older children/adults.
Epidemiology and causes

Atopic eczema is the most common inflammatory skin disease of childhood in developed countries, affecting 15 to 20% of children in the UK at any one time (Hoare 2000). Two-thirds of people with the disease have a family history of atopic eczema, asthma or hay fever. The cumulative prevalence of atopic dermatitis varies from 20% in Northern Europe and the USA to 5% in the South-Eastern Mediterranean (Thorsrup 2002). Prevalence data for the symptoms of atopic eczema were collected in the global ISAAC study (International Study of Asthma and Allergies in Childhood). The results of this study suggest that atopic eczema is a worldwide problem affecting 15 to 20% of children (Williams 1999). Of those children with atopic eczema, only 2% under the age of 5 years have severe disease and 84% have mild disease (Emerson 1998). Two per cent of adults have atopic eczema and many of these have a more chronic and severe form (Charman 2002). Atopic eczema is often associated with other atopic diseases e.g. asthma and rhinitis (Beck 2000). The incidence of common allergenic disease has increased in the past 30 years (Fendrick 2001) and the increase in prevalence of atopic disease in the past 3 decades appears to be a real phenomenon and has been observed in countries as far apart as Japan, USA, Finland and Africa (Williams 1992). The cause of eczema is not well understood and probably is due to a combination of genetic and environmental factors (Cookson 2002). In recent years research has pointed to the possible role of environmental agents such as house dust mite (Van Bever 2002), pollution (Polosa 2001), and prenatal or early exposure to infections (Kalliomaki 2002). Food allergy may be common in atopic eczema especially if the eczema is severe (Guillet 1992; Zeiger 1995; Eigenmann 1998).

Natural history

Atopic eczema usually starts within the first 6 months of life, and by 1 year, 60% of those likely to develop it will have done so. Remission occurs by the age of 15 years, in 60 to 70% of cases, although some relapse later. In the more severely affected child, development and puberty may be delayed (Baum 2002). Many children with eczema go on to develop asthma and hay fever, which might also be triggered by food allergy (Ricci 2006).

Impact

Atopic eczema varies in severity, often from one hour to the next. Severity can be measured in a number of ways. A systematic review of named outcome scales for atopic eczema found that of the 13 named scales in current use, only one (Severity Scoring of Atopic Dermatitis, SCORAD) had been fully tested for validity, repeatability and responsiveness (Charman 2000). Itching and scratching can adversely affect quality of life through chronic sleep disturbance. This may have an impact on family life. The disease can be associated with complications such as bacterial and viral infections (McHenry 1995). The unsightly appearance of the skin and the need to apply greasy ointments can limit a child’s inclination to participate in social and sporting activities and thus affect their confidence. Adults with atopic eczema often have low self-esteem and relationships can be difficult to initiate and sustain. Everyday tasks such as housework, gardening, childcare and food preparation present problems when the skin on the hands is cracked.
Promotion at work may be blocked for people who do not ‘look good’. There is a substantial economic cost not only to the family of the person with atopic eczema (Kemp 2003) but also to the health services of the country as a whole (Herd 1996; Verboom 2002). Direct costs to the family are encountered when purchasing treatments, special clothing and bedding; indirect costs are experienced from lost working days when parents are looking after a sick child. The wider economic implications lie in the costs of health professionals, the lost opportunities of parents of sick children who do not have the option of seeking employment and the child who, as a result of missing schooling, has limited employment prospects (Su 1997).

**Description of the intervention**

There is currently no cure for atopic eczema. However a wide range of treatments are employed which aim to control the symptoms (Fennessy 2000; Hoare 2000; Lamb 2002). Health professionals assist people in the management of their disease using a variety of treatment methods; these include emollients, topical steroids, topical tars, topical tacrolimus and pimecrolimus. Other treatments such as wet wrap dressings, phototherapy and complementary therapies are also tried (Ernst 2002). Many of the treatments are of unknown effectiveness (Hoare 2000). Emollients and topical corticosteroids are universally recommended (Smethurst 2002)

**How the intervention might work**

**Diet and atopic eczema**

Food hypersensitivity may be the first stage in the development of ‘allergic diseases’ such as atopic eczema (Chandra 2002). Food allergy may be an important factor in up to 20% of children with atopic eczema under 4 years (Oranje 2000). The incidence of food allergy is highest around the age of six to nine months. Many clinicians have found that elimination of specific foods found by food challenge to elicit symptoms can lead to significant improvement in eczematous symptoms (Sampson 2003). Challenges in people with food allergies can lead to eczematous lesions and infiltration of allergic inflammatory cells and animal studies have suggested that eczema may be caused by food allergies (Li 2001).

However, many food reactions in people with atopic eczema may not necessarily be mediated through immune reactions (David 2000). As sensitisation to food early in life may be a predisposing factor (Baena-Cagnani 2001) it is important to investigate whether the elimination of dietary triggers could help to alleviate the symptoms of atopic eczema. The role of dietary factors in atopic eczema either as a cause or as a treatment, through the use of exclusion diets, remains unclear (Oranje 2000). Many trialists advocate double blind placebo controlled food challenges to establish whether a child has a true food allergy (Sampson 1992). There is a vast amount of literature claiming that dietary elimination causes improvement of atopic eczema in some cases. However, much of the evidence fails to withstand close scrutiny (David 2000).

There are three main types of dietary exclusion (David 2000):

1. the simple elimination of cow’s milk protein and egg;
2. the few foods’ diet (a diet in which all but a handful of foods is excluded) (David 1993). One problem with the ‘few foods diet’ is poor adherence because the diet is so restrictive (Hathaway 1983; David 1989);
3. the ‘elemental’ diet, more accurately described as a non-macromolecular diet since ordinary foodstuffs are all avoided, and the participant receives a liquid diet which contains amino acids, carbohydrate, fat, minerals and vitamins. The palatability of the elemental formula is poor.

Many people, with or without their doctor’s or dietician’s help, experiment by excluding a particular food suspected of causing a reaction for a variable time. Most investigators would base elimination diets upon proven food allergies, either by challenge or serum food-specific IgE antibodies exceeding specific diagnostic decision points (Sampson 2001). The advantage of dietary interventions is that they may address one of the primary causes, as opposed to merely suppressing the symptoms, although there can be serious consequences to any dietary manipulation that leaves the individual deficient in calories, protein or minerals such as calcium. (David 1984; Devlin 1989). Avoidance of multiple foods is potentially hazardous and requires continued paediatric and dietary supervision (David 1984). The role of food is much debated in atopic eczema, but the allergenic relevance of some proteins seems to be important only in a small number of people, especially in the first years of life (Svejgaard 1985).

**Why it is important to do this review**

The rationale for a review on dietary exclusions for established atopic eczema is:

- currently there is no cure for atopic eczema;
- diets excluding foods, such as cow’s milk, are commonly tried (Graham-Brown 2000);
- the place for dietary elimination in the short-term management of atopic eczema is unclear (Smethurst 2002);
- some have claimed that there is no evidence of long-term benefit from dietary elimination (David 2000).

**OBJECTIVES**

To assess the effects of general dietary avoidance practices for the treatment of established atopic eczema.
METHODS

Criteria for considering studies for this review

Types of studies
We included randomised controlled trials (RCTs) of dietary exclusion for the treatment of established atopic eczema/dermatitis. We excluded double blind placebo controlled food challenges conducted in isolation, since these are not therapeutic trials but diagnostic or provocation tests. Comparisons considered were active exclusion diet vs control or a comparison of two active diets.

Types of participants
We included participants who had atopic eczema diagnosed by a doctor. In the National Health Service Technology Assessment (HTA) systematic review of treatments for atopic eczema (Hoare 2000), specific terms were used to identify trial participants as listed in Table 1. The list classifies conditions into ‘definite’, ‘possible’ and ‘not’ atopic eczema and we have used this list as a guide. We excluded those studies using terms in the ‘not atopic eczema’ category such as ‘allergic contact eczema’. We found some studies using terms in the ‘possible atopic eczema’ category, such as ‘childhood eczema’. One or more authors scrutinised these and we included them if the description of the participants clearly indicated atopic eczema (i.e. itching and flexural involvement).

Types of interventions
We included studies with exclusions of any type of food, either singly or in combination with other foods.

Types of outcome measures

Primary outcomes
(a) Short-term (within six weeks). Changes in parent-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss.
(b) Degree of long-term (over six months) control, such as reduction in number of flares or reduced need for other treatments.

Secondary outcomes
(a) Global severity as rated by the participants or their physician. Where the outcome was not available then the following was used:
(b) Global changes in composite rating scales using a published named scale

Tertiary outcome measures
Changes in individual signs of atopic eczema as assessed by a physician e.g. erythema (redness), purulence (pus formation), excoriation (scratch marks), xerosis (skin dryness), lichenification (thickening of the skin), fissuring (cracks), exudation (weeping serum from the skin surface), crusts (dried serum on skin surface), infiltration/oeoeema (swelling of the skin), induration (a thickened feel to the skin).

Search methods for identification of studies

Electronic searches
We searched the Cochrane Skin Group Specialised Register (March 2006) using these terms: ((atopic AND eczema) OR (atopic AND dermatitis) OR (besnier* AND prurigo) OR (neurodermatitis) OR (infant* AND eczema) OR (childhood AND eczema) OR eczema) AND (diet* or (dietary and manipulation) or (diet* and therap*) or (milk and exclusion) or (egg and exclusion) or (food and allerg*))
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 1, 2006) using the strategy in Appendix 1
We searched MEDLINE (2003 to March 2006) using the strategy in Appendix 2
We searched EMBASE (2003 to March 2006) using the strategy in Appendix 3
We searched LILACS (Latin American and Caribbean Health Science Information database) (to March 2006) using the terms Eczema atópico [Palavras do título] or Dermatitis atópica [Palavras do título]
We searched PsycINFO (1806 to March 2006) using the strategy in Appendix 4
We searched AMED (Allied and Complementary Medicine) (1985 to March 2006) using the strategy in Appendix 5
We searched ISI Web of Science (March 2006) using the terms atopic eczema and diet
Searching other resources

References from published studies
References from published studies were checked for further trials.

Unpublished literature
Where possible unpublished, on-going trials were obtained via correspondence with the trial authors. The metaRegister of Controlled Trials www.controlled-trials.com, www.clinicaltrials.gov and www.nottingham.ac.uk/ongoingskintrials were searched in March 2006 for ongoing trials using the terms atopic eczema, atopic dermatitis.

Pharmaceutical companies
Pharmaceutical companies were contacted, where appropriate, for reviews or unpublished trials.

Language
No language restrictions were imposed and translations were obtained where possible.

Data collection and analysis

Selection of studies
One author (FD) ran the searches, then two authors (FB-H and FD) checked the titles and abstracts for relevance. Three authors (FB-H, HW and FD) then independently assessed the full text of the identified RCTs and decided whether they fitted our inclusion criteria. Where there were any disagreements they were resolved by discussion between the authors. Where there were missing data from the trials we contacted the trial authors.

Data extraction and management
Two authors (FB-H and FD) independently extracted the data using a data extraction form for consistency. We resolved any discrepancies by discussion. One author (FB-H) entered the data.

Assessment of risk of bias in included studies

Our quality assessment included an evaluation of the following components for each included study, since there is some evidence that these are associated with biased estimates of treatment effect (Juni 2001):

(a) the method of generation of the randomisation sequence;
(b) the method of allocation concealment - it was considered ‘adequate’ if the assignment could not be foreseen;
(c) who was blinded/not blinded (participants, clinicians, outcome assessors);
(d) how many participants were lost to follow up in each arm, and whether participants were analysed in the groups to which they were originally randomised (intention to treat).

In addition, the quality assessment also included:

(e) degree of certainty that the participants had atopic eczema;
(f) baseline comparability of the participants for age, sex and eczema severity;
(g) assessment of compliance with treatment.

We recorded the information in a table of quality criteria Table 2 and a description of the quality of each study is given based on a summary of these components.

Measures of treatment effect
For studies with a similar type of intervention, we performed a meta-analysis, to calculate a weighted treatment effect across trials, using a random effects model. We have expressed the results as risk ratio (RR) and 95% confidence intervals (CI) for dichotomous outcomes and mean differences (MD and 95% CI) for continuous outcomes. The results are also expressed as number needed to treat (NNT) where appropriate, for a range of plausible control event rates. Where it has not been possible to perform a meta-analysis the data have been summarised for each trial.

Unit of analysis issues
Where paired data were available for cross-over studies we calculated the conditional odds ratio with 95% CI using the methodology as described by Elbourne 2003. If paired data were not available then data, where available, were taken from the first phase of the cross-over study and if appropriate then the first phase was treated as a parallel study. Cross-over studies are not ideal for dietary exclusion studies since carry-over effects may invalidate data in the second period. Non-randomised controlled studies are listed but not discussed further. Studies relating to adverse effects are described qualitatively.

Assessment of heterogeneity
Heterogeneity was assessed using $I^2$.

Data synthesis
Where participant-rated symptoms were reported on categorical Likert scales (e.g. no improvement, mild improvement, good improvement, excellent), we dichotomised the data by defining a cut-off at ‘good to excellent improvement’. Where data were reported on continuous scales (e.g. number of days sleep loss), we regarded...
a 20% reduction/improvement compared to control as being clinically significant. Not enough studies used SCORAD for us to be able to split eczema severity into mild, moderate and severe where mild is 0 to 15, moderate is 15 to 40 and severe is >40. Where data on existing medication usage were included, we have attempted to see whether this has increased differentially in one of the treatment arms as the main dietary intervention has proceeded.

Subgroup analysis and investigation of heterogeneity
Where substantial heterogeneity ($I^2>50\%$) existed between studies for the primary outcome, we have explored the reasons for heterogeneity, such as disease severity, whether food allergy was confirmed by a prior provocation/serum test, dosage etc. In future updates of this systematic review, we will perform further subgroup analysis, where there is sufficient information to do so. This will be done in those studies of infants (under one year old) and children (aged 1 to 16 years) versus adults and for those participants who had a positive food challenge prior to entry into the trial.

Sensitivity analysis
We may also conduct sensitivity analyses to examine the effects of excluding poor quality studies, defined as those studies that do not clearly report the randomisation process, blinding and no intention to treat.

Other
Where there was uncertainty, we contacted trial authors for clarification.

RESULTS

Description of studies
See: Characteristics of included studies; Characteristics of excluded studies.

Results of the search
We identified 12 RCTs of which 9 were included.

Included studies
Only two studies were considered sufficiently similar to pool (Isolauri 1995; Niggemann 2001).

The studies fell into three main categories - see 'Characteristics of included studies'.
1. Egg and cow's milk exclusion diets
2. Few foods diet
3. Elemental diet

1. Egg and cows milk exclusion diets
Six RCTs, three of which were cross-over studies (Atherton 1978; Cant 1986; Neild 1986) and three were parallel studies (Isolauri 1995; Lever 1998; Niggemann 2001)
   • Egg and cow's milk exclusion diet (with soya substitute) vs egg and cows' milk (Atherton 1978)
   • Egg and cow's milk exclusion diet (with soya substitute) vs egg and cows' milk in breastfeeding mothers (Cant 1986)
   • Whey hydrolysate vs amino acid derived formula (Isolauri 1995)
   • Egg and cow's milk exclusion diet (with soya substitute) vs normal diet (Neild 1986)
   • General advice on care of atopic eczema and specific advise about egg exclusion diet vs general advise from dietician only (Lever 1998)
   • Amino-acid-based (AA) formula vs extensively hydrolysed whey formula (Niggemann 2001)

2. Few foods diet
One RCT, a parallel study
   • Few foods diet plus whey hydrolysate vs few foods diet plus casein hydrolysate versus usual diet (Mabin 1995)

3. Elemental diet
Two RCTs, one was a cross-over study (Leung 2004) and one was a parallel study (Munkvad 1984)
   • Elemental diet vs blended diluted diet of foodstuffs consumed by hospital inpatients (Munkvad 1984).
   • Hypoallergenic, milk free lactose and sucrose-free, complete elemental formula with free amino-acid (AA) vs participants pre-existing formula (Leung 2004).

Excluded studies
We excluded three studies (see Characteristics of excluded studies) as they did not fit our inclusion criteria for ‘types of intervention’ (Majamaa 1997; Isolauri 2000; Kirjavainen 2003).

Risk of bias in included studies
Four studies were randomised, controlled, cross-over designs (Atherton 1978; Cant 1986; Neild 1986; Leung 2004). Five studies were randomised controlled parallel designs (Munkvad 1984; Mabin 1995; Isolauri 1995; Lever 1998; Niggemann 2001).
**Allocation**

In seven of the studies in this review the method of randomisation was not described at all or was unclear. Two of the studies used a random number table (Cant 1986; Mabin 1995). In none of the studies did the trial authors clearly demonstrate adequate concealment of allocation.

**Blinding**

Only one study blinded participants, clinicians and outcome assessors (Munkvad 1984). Two studies blinded participants and outcome assessors (Atherton 1978; Neild 1986). Three studies blinded the outcome assessor only (Mabin 1995; Lever 1998; Leung 2004). In three studies blinding was unclear (Cant 1986; Isolauri 1995; Niggemann 2001).

**Incomplete outcome data**

Analysis should be performed according to the intention-to-treat principle, thus avoiding bias (Sackett 1979; May 1981; Altman 1991). However in many of the studies analysis of outcome was carried out only in those participants who completed the study. Only one study analysed by intention-to-treat (Isolauri 1995). For one study (Niggemann 2001) it was impossible to know if the analysis was intention-to-treat as no results tables were given or numbers mentioned in the text. All but two studies stated numbers and reasons for participants lost to follow up. One study (Isolauri 1995) had no loss to follow up, possibly due to the highly selected population.

**Other potential sources of bias**

**Degree of certainty that participants had (atopic eczema) AE**

The certainty of AE was clear for four studies (Munkvad 1984; Cant 1986; Mabin 1995; Niggemann 2001) that used criteria by Hanifin or Yates. One study stated that they included clinically typical AE (Atherton 1978) and all the other studies did not state how they diagnosed AE.

**Baseline comparability of the participants for age, sex, and eczema severity**

In one study the diet group had slightly more extensive and more severe involvement than the controls (Lever 1998). Two studies clearly stated that there were no differences in baseline comparability (Mabin 1995; Niggemann 2001). For all other studies it was not clear if there was baseline comparability of the participants.

**Assessment of compliance**

Compliance was clear in only three studies (Munkvad 1984; Neild 1986; Mabin 1995).

**Severity of AE**

Severity of AE was clear for only one study (Munkvad 1984).

**Effects of interventions**

The secondary outcome measures: (a) Global severity as rated by the participants or their physician, (b) Global changes in composite rating scales using a published named scale and (c) The trial author’s modification of existing scales or new scales, have not been listed as we originally planned. This is because it was not possible to exactly match these outcomes with what we actually found. Instead we described the disease activity as we found it in each of the studies.

1. **Egg and cows milk exclusion diets**

Six RCTs of which three were cross-over studies and three were parallel studies.

**Cross-over studies**

All three studies (Atherton 1978; Cant 1986; Neild 1986) were conducted in different populations. One study was conducted in children of 2 to 8 yrs (Atherton 1978), one in breastfeeding mothers and babies (Cant 1986), and one in children and adults 1 to 23 yrs (Neild 1986). Three studies used soya milk as a control food which in itself can be allergenic in AE. All studies measured severity of AE in different ways. For these reasons the studies were not considered suitable to pool.

**Atherton 1978**

The first cross-over study (Atherton 1978) of 36 unselected children (2 to 8 yrs) compared a soya based preparation (egg and milk exclusion) vs dried egg and cows’ milk over three four-week periods. Main outcomes were eczema activity and area (using unpublished scale) pruritus, sleeplessness and antihistamine usage.

**Primary outcome measures**

(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss.

Pruritus improved during the trial diet compared to the control diet. A small non significant order effect (i.e. improvements greater at the end of the first versus the second period whatever the diet content) with pruritus scores being lower during the first diet period than during the second diet period.
Sleeplessness was significantly lower during the trial period as compared to control period (p < 0.05), and the order effect was greater than the treatment effect.

(b) Reduced need for other treatments.
Significantly fewer antihistamine tablets were used in the trial diet period.

(2) Secondary outcome measures

Eczema area and activity (using unpublished composite score assessed by physician).
Eczema activity scores (major improvement +2; minor improvement +1; no change 0; minor deterioration -1; major deterioration -2) which recorded change of eczema activity during each diet period showed significantly more improvement after the trial diet than after control diet (p < 0.001). A significant order effect was apparent but this was smaller than the treatment effect.

Area scores (the body surface was divided into 20 separate zones, each of which was recorded as affected or unaffected; this gave an area score of up to 20) improved significantly during the trial period (p < 0.005). A significant order effect was apparent but this was smaller than the treatment effect.

From the paper we were able to calculate the difference between the proportions of children whose activity score improved and those whose score did not improve, based on paired observations from the same individual. Eczema activity scores improved significantly for children on the exclusion diet as compared to the control diet (Conditional OR 10.52, 95% CI 2.27 to 48.80; Analysis 1.1).

(d) Quality of life
No data given

(e) Palatability of the diet.
No data

(f) Adverse events
Three participants (all on control diet) experienced a severe exacerbation of eczema within a few days of starting their diet.

Cant 1986
The second cross-over study (Cant 1986) in 19 unselected breast feeding mothers and babies (6 weeks to 9 months of age) compared a soya based preparation (egg and milk exclusion) vs egg and milk diet over three four-week periods. Due to insufficient data we were unable to calculate the conditional odds ratio for this study or analyse the first period only as from a parallel group trial.

1) Primary outcome measures
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss.
No data
(b) Reduced need for other treatments.

There was no significant difference in the amount of steroid cream applied in each period.

(2) Secondary outcome measures

Two continuous scale eczema severity scores: area (number of involved body areas from 0 to 20) and activity (severity within each areas on 0 to 3 scale x number of involved areas)
Mean eczema severity scores decreased during the trial and at the end of the study when the mothers returned to a normal diet for four weeks. The scores were significantly lower than they had been at the beginning (p < 0.01).
There was a marked period effect in that children of mothers on the normal diet in the third period continued to improve.
(d) Quality of life
No data given
(e) Palatability of the diet.
No data given
(f) Adverse events
Two mothers withdrew - one mother vomited after soya milk and another mother's baby developed eczema and bloody diarrhoea within 24 hours of her taking the diet containing cows milk and egg. One infant developed watery stools with mucus when his mother took the substitute containing cow's milk and egg.

Neild 1986
A third cross-over study (Neild 1986) in 53 unselected children and adults (1 to 23 yrs) compared a cow's milk exclusion diet (soya milk) vs milk containing egg and cows milk for 6 weeks. Due to insufficient data we were unable to calculate the conditional odds ratio for this study or analyse the first period only as from a parallel group trial.

1) Primary outcome measures
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss.
The trial authors reported no significant difference in total itch score at end of trial diet compared to end of normal diet
(b) Reduced need for other treatments.
More topical steroids were used while on the trial diet.

(2) Secondary outcome measures

The body surface was divided into 20 zones using the method of Atherton 1978, and the presence of acute eczema (erythema and vesiculation) and chronic eczema (lichenification and prurigo papules) was noted, both on a scale from 0 to 3.

The trial authors reported that no statistically significant difference was shown between the scores at the end of the trial diet compared with those at the end of the normal diet or between the scores at...
the end of the trial diet compared with those at the end of the control diet.

At the end of the study 25% (10/40) of adults and children appeared to have improved on the trial diet and had lower area scores and itch scores than on the normal diet or on the control. Of those who responded, five were in the youngest age group and two were non-Caucasians. More responders had the trial diet first than the group as a whole.

(d) Quality of life
No data given
(e) Palatability of the diet.
No data given
(f) Adverse events
One participant developed gastrointestinal symptoms followed by itch and exacerbation of eczema

Parallel studies
(Isolauri 1995; Lever 1998; Niggemann 2001). Two of these three studies were considered sufficiently similar to pool.

Isolauri 1995 and Niggemann 2001
The first study (Isolauri 1995) was in a population of 45 infants (6 to 7 months) with a positive reaction to cow's milk challenge that compared eHF (extensively hydrolysed whey formula) vs AA (amino acid formula) containing no peptides for 9 months.

The second study (Niggemann 2001) in 73 infants (1 to 10 months) with a cows' milk allergy/intolerance (proved by a double-blind, placebo controlled food challenge), compared an AA formula vs eHF for 6 months.

1) Primary outcome measures
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss.
No data for either study
(b) Degree of long-term (over six months) control, such as reduction in number of flares or reduced need for other treatments.
No data for either study

2) Secondary outcome measures
Area affected (% of total skin area) using 'rule of nine'
Severity score in arbitrary units which assesses six clinical features (extent, erythema, oedema/papulation, oozing/crusts, dryness, lichenification) on a scale of 0 to 3 units at 16 body sites.
At the end of the study 51% of the children had a significant improvement in body surface area with the exclusion diet compared to normal diet (RR 1.51, 95% CI 1.07 to 2.11; Analysis 3.1).
Change in surface area and severity score (6 clinical features on a scale of 0 to 3 units at 16 body sites) was significantly improved in the egg exclusion diet group as compared to the normal diet at the end of 6 weeks and end of treatment (MD 5.50, 95% CI 0.19 to 10.81; Analysis 3.2 and MD 6.10, 95% CI 0.06 to 12.14; Analysis 3.3) respectively.
(d) Quality of life
No data available
(e) Palatability of the diet
No data available
(f) Adverse events including long term consequences on growth
No data available

2. Few foods diet
One RCT, which was a parallel study (Mabin 1995), randomised 85 children (0.3 to 13.3 yrs), with atopic eczema affecting more than 12% of the body, to one of three groups:
i) few foods diet (eliminating all but five to eight foods) plus whey;
ii) few foods diet plus casein hydrolysate; or
iii) usual diet.

1) Primary outcome measures
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss.
There was no significant difference in daytime itch when comparing: few foods diet with casein compared to normal diet (MD -0.6, 95% CI -1.46 to 0.26; Analysis 5.1); few foods diet with whey compared to few foods with casein (MD 0.5, 95% CI -1.69 to 2.69; Analysis 6.1); few foods with whey vs normal diet (MD -0.10, 95% CI -2.22 to 2.02; Analysis 4.1). There were no significant differences in sleep disturbances at 6 weeks for: few foods with whey vs normal diet (MD -0.30, 95% CI -2.51 to 1.91; Analysis 4.2); few foods with casein vs normal diet (MD -0.10, 95% CI -0.90 to 0.70; Analysis 5.2); few foods with whey vs few foods with casein (MD -0.20, 95% CI -2.50 to 2.10; Analysis 6.2).

(2) Secondary outcome measures
There were no significant differences in body surface area affected at 6 weeks when comparing: few foods and casein diet vs normal diet, (MD -0.10, 95% CI -18.91 to 18.71; Analysis 5.3); few foods and whey vs normal diet (MD -12.90, 95% CI -31.21 to 5.41; Analysis 4.3); few foods and whey vs few foods and casein (MD -12.80, 95% CI -36.75 to 11.15; Analysis 6.3). There were no significant differences in skin severity score at 6 weeks when comparing: few foods and whey diet vs normal diet (MD -5.9, 95% CI -29.35 to 17.55; Analysis 4.4); few foods and casein diet vs normal diet (MD -2.40, 95% CI -22.64 to 27.44; Analysis 5.4); few foods and whey diet vs few foods and casein diet (MD -8.3, 95% CI -37.62 to 21.02; Analysis 6.4).

d) Quality of life
No data given
e) Palatability of the diet
No data given
(f) Adverse events including long term consequences on growth
No data given

3. Elemental diet
Two RCTs, one was a cross-over study (Leung 2004) and one was a parallel study (Munkvad 1984). Munkvad 1984

The first study (Munkvad 1984) randomised 33 adults (16 to 25 yrs) to either an elemental diet (amino acids, essential fatty acids, glucose, trace elements, sorbic acid and vitamins) or a blended diluted diet of foodstuffs consumed by hospital inpatients. Participants remained in hospital for the three week study.

1) Primary outcome measures
(a) Short-term (within six weeks). Changes in participant-rated or mother-rated symptoms of atopic eczema such as itching (pruritus) or sleep loss. Short-term (within six weeks).

There was no significant difference between the two groups for the combined outcome of pruritus, sleeplessness and antihistamine usage (RR 1.69, 95% CI 0.2 to 13.93; Analysis 7.2)

2) Secondary outcome measures
There was no significant difference at three weeks between the two groups for improvement of intensity and extension of the eczema (RR 0.7, 95% CI, 0.25 to 1.97; Analysis 7.1) measured by a major activity score. A major activity score of >100 was the criterion for a positive response to treatment. However there was a non significant trend in favour of the normal diet.

(e) Quality of life
No data given

(f) Adverse events including long term consequences on growth
No data given

Leung 2004
A cross-over study (Leung 2004) in 15 children (< 3 yrs) compared hypoallergenic, milk-free, complete elemental formula with free AA (trial milk) vs participants pre existing formula (placebo) for 6 weeks.

1) Primary outcome measures
No data given

2) Secondary outcome measures
Eczema activity score
Median changes for SCORAD and its area, intensity pruritus and sleep loss components as well as global health score were reported not to be statistically significant during the active or placebo phase.

d) Quality of life
No data given

(e) Palatability of the diet
No data given

(f) Adverse events including long term consequences on growth
No data given

DISCUSSION

Summary of main results
We found some evidence to support the use of an egg-free diet in infants with a suspected egg allergy who have a positive specific IgE to eggs in their blood. This perhaps highlights the importance of allergy testing beforehand. Only 2 of the other 11 included studies tested for food allergy (Isolauri 1995; Niggemann 2001), but those studies dealt with comparisons of 2 different forms of exclusion diets rather than a comparison of an exclusion diet versus...
normal diet, and have therefore not contributed to the question of whether any form of exclusion diet is helpful in such people. The other included studies of unselected people with atopic eczema did not find any evidence of benefit for exclusion diets. It is useful to know that exclusion diets given to unselected people with atopic eczema are not likely to be helpful, as benefit from dietary exclusions could be due to non-allergic mechanisms. Not showing any benefit from such dietary exclusions in unselected people does not mean they are not helpful in people with proven allergy to that particular food. Three of the RCTs used potentially allergenic soya based milk substitute which itself can be allergenic in atopic eczema. Adverse events for people on exclusion diets included gastrointestinal symptoms followed by exacerbation of eczema or just exacerbation of eczema.

Overall completeness and applicability of evidence

This systematic review has only addressed dietary exclusion and has not addressed dietary supplements including probiotics which are the subject of another review. The clinical importance of changes in severity scores obtained in many studies is unknown. Dropout rates are particularly high for elimination diets and those containing hydrolysate milk substitutes and this will always remain a problem. Overall interpretation of the above studies was difficult due to the poor methodological quality of the studies.

Quality of the evidence

Nine poor quality studies were included in the review involving 421 participants: 6 egg and cow's milk exclusion diets; 1 was a few foods diet; 2 were elemental diets.

Of the egg and cow's milk exclusion diets, three studies used soya based milk substitute which itself can be allergenic in atopic eczema. Three small cross-over studies studied various populations ranging from infants to adults. Only two studies followed participants for more than six months. Long-term outcomes and consequences of an egg and milk free diet were not discussed by any of the studies. One study in unselected breast feeding mothers and babies found an improvement in their babies eczema during the exclusion period and when they went back to their normal diet - however possible improvement may well have been spontaneous. One small study in unselected children found a significant improvement in eczema severity during the trials period when an egg and milk exclusion diet was compared to an egg and milk diet, however just under half of the participants were not included in the final analysis. One study in infants (11 to 17 months) with sensitivity to eggs found a significant improvement in body surface area with the exclusion diet compared to normal diet.

One study of the few foods diet found no significant change in body surface area, skin severity score, sleep disturbances in children when few foods diet plus whey compared to few foods diet plus casein hydrolysate or usual diet.

Two elemental diet studies were unable to find any significant difference in eczema severity when an elemental diet was compared to a normal hospital diet in adults or when an elemental diet was compared to a pre existing formula in children. Elemental diets are difficult since they are unpalatable for many and required hospitalisation and dietetic input.

Potential biases in the review process

Very few studies have been found and in seven of the included studies the method of randomisation was not described at all or was unclear.

Agreements and disagreements with other studies or reviews

The results of this review are in agreement with a previous HTA review (Hoare 2000).

Authors' Conclusions

Implications for practice

Elimination diets can be difficult to follow. The studies were performed in different populations with only one study giving results on the severity of atopic eczema. The clinical importance of small changes in severity scores obtained in many studies is unknown. Although diets excluding foods such as cows' milk are commonly tried there is little evidence for benefit in their use in unselected people with atopic eczema. That does not mean to say that they could not be beneficial in people with proven cows' milk allergy, but such studies have not been done yet. There may be some benefit in the use of an egg-free diet in infants with a suspected egg allergy who have a positive specific IgE to eggs in their blood. There does not appear to be any benefit in the use of elemental or few foods diet in unselected people with atopic eczema.

Implications for research

Future studies should be big enough to answer the questions posed, and well reported according to CONSORT guidance (Moher 2001). Common sense suggests that studies of food allergy exclusions should be done on people with a history of suggested food allergy, confirmed by appropriate allergy testing or challenge tests. A distinction should be made between young children, older children and adults, because food allergy in children tends to improve in time. Disease severity should be measured using valid instruments and include quality of life assessments and patient-centred...
A C K N O W L E D G E M E N T S

REFERENCES

References to studies included in this review

Atherton 1978 [published data only]

Munkvad 1984 [published data only]

Leung 2004 [published data only]

Cant 1986 [published data only]

Isolauri 1995 [published data only]

Lever 2004 [published data only]

Mabin 1995 [published data only]

Munkvad 1984 [published data only]

The authors would like to thank Rosemary Humphries who contributed to the development of the protocol and the final readability of the review and to Weiija Zhang who read and commented on the final protocol.

The editorial base would like to thank the following people who were the external referees for this review: Hugh Sampson and Peter Arkwright (content experts) and Shirley Manknell and Carol O’Brien (consumers).

Additional references

Altman 1991

Archier 2000

Baena-Cagnani 2001
Dietary exclusions for established atopic eczema (Review)

Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Baum 2002

Beck 2000

Bohme 2001

Chandra 2002

Charman 2000

Charman 2002

Chren 1997

Cookson 2002

David 1984

David 1989

David 1993

David 2000

Devlin 1989

Eigenmann 1998

Elbourne 2003

Emerson 1998

Ernst 2002

Fendrick 2001

Fennessy 2000

Finlay 1996

Flohr 2004

Graham-Brown 2000

Guillet 1992

Hathaway 1983

Herd 1996
Sampson 2001

Sampson 2003

Smethurst 2002

Su 1997

Sveigaard 1985

Therstrup 2002

Van Bever 2002

Verboom 2002

Williams 1992

Polosa 2001

Ricci 2006

Sackett 1979

Sampson 1992

Sampson 2001

Sampson 2003

Smethurst 2002

Su 1997

Sveigaard 1985

Therstrup 2002

Van Bever 2002

Verboom 2002

Williams 1992

Polosa 2001

Ricci 2006

Sackett 1979

Sampson 1992

Sampson 2001

Sampson 2003

Smethurst 2002

Su 1997

Sveigaard 1985

Therstrup 2002

Van Bever 2002

Verboom 2002

Williams 1992
Williams 1999

Zeiger 1995
Zeiger R, Heller S. The development and prediction of atopy in high-risk children: Follow up at seven years in a prospective randomised study of combined maternal and infant food allergen avoidance. *Journal of Allergy and Clinical Immunology* 1995;95:1179–90.

* Indicates the major publication for the study
Characteristics of included studies  [ordered by study ID]

Atherton 1978

<table>
<thead>
<tr>
<th>Methods</th>
<th>UK, Single centre. RCT. D: cross over AC: unclear RS: unclear B: participant and outcome assessor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Setting: outpatients. Unselected children (n=36), Evaluable: (n=20). Age 2-8 yrs SAE: unknown Dig: Typical AE C0-T: hydrocortisone, emollients, antihistamine</td>
</tr>
<tr>
<td>Interventions</td>
<td>Three four week periods. During first and third period participants were placed on an egg and milk elimination diet and they were randomly allocated to one of two milk substitutes. During 1 period the participants were given a dried soya-based preparation (trial period), during the other they were given a preparation containing a mixture of dried egg and cows’ milk (control period). During the middle period participants resumed their normal diet, to minimise any carry-over effect</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Eczema area and activity (using unpublished composite score assessed by physician), degree of adherence to diet, skin prick tests, pruritus, sleeplessness and antihistamine usage</td>
</tr>
<tr>
<td>Notes</td>
<td>PP.16 loss to FU(44%). Nine excluded due to dietary lapses, seven withdrew voluntarily (four during or after control period, three during or after trial period), . Marked order effect i.e. improvements greater at end of first vs second period whatever the diet content. Soya milk (which itself can be allergenic in atopic eczema) used as ‘control’ food</td>
</tr>
</tbody>
</table>

Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

Cant 1986

<table>
<thead>
<tr>
<th>Methods</th>
<th>UK, Single centre. RCT D: cross over AC: unclear RS: random number table B: unclear</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Setting: unclear. Unselected breast feeding mothers and babies (n=19), (8 infant girls and 9 infant boys) Evaluable: (n=17) Age 6 wks -6 mths SAE: unknown Dig: according to Yates et al. Co-T: topical steroids and emollients</td>
</tr>
</tbody>
</table>
Cant 1986  (Continued)

| Interventions | Twelve week study divided into three four week periods; during first two periods, mothers excluded cows’ milk, egg and other foods (chocolate, wheat, nuts, fish, beef, chicken, citrus fruits, colourings and preservatives) from their diet. In the first period mothers were randomised to one of two milk substitutes containing either cows’ milk and egg or just soya. Normal diet in third period |
| Outcomes | Two continuous-scale eczema severity scores evaluated after four weeks on each diet: area (number of involved body areas from 0-20) and ‘activity’ (severity within each area on 0-3 scale x number of involved areas) |
| Notes | ITT attempted. two mothers withdrew - one vomited after soya milk, another mothers baby developed eczema and bloody diarrhoea. First study described as double-blind, though almost half mothers correctly identified substitutes. Soya used as control diet. Marked period effect in that children of mothers on normal diet in third period continued to improve |

**Risk of bias**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

Isolauri 1995

| Methods | Finland, Single centre. RCT D:parallel AC:unclear RS: unclear B:unclear |
| Participants | Setting: outpatients. Infants (n=45) who were not being breast-fed, who had been fed substitute cows’ milk for at least 6 months and who showed a positive reaction to a masked challenge with cows’ milk Evaluable:45 Age 6-7 months SAE: Dig: Hanifin C0-T: |
| Interventions | eHF (n=22) vs amino acid derived formula containing no peptides (n=23) |
| Outcomes | Severity of atopic eczema measured by SCORAD. Infants growth also measured FU: 9 months |
| Notes | ITT. No loss to FU. Highly selected population Study mainly concerned in comparison of growth in AA vs eHF Main statistical comparison of change in eczema severity between the two groups not reported in results, though children in AA group higher baseline scores |

**Risk of bias**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>
### Leung 2004

| Methods          | Hong Kong, single centre. RCT  
|                  | D: cross over  
|                  | AC: unclear  
|                  | RS: unclear  
|                  | B: outcome assessor blinded  
| Participants     | Setting: paediatric allergy and dermatology clinics. Unselected children (n=15)  
|                  | Evaluable: (n=11)  
|                  | Age <3 yrs  
|                  | SAE: unclear  
|                  | Dig: according to Hanifin criteria  
|                  | Co-T: all drugs including topical corticosteroid mometasone furoate and oral sedating antihistmines  
| Interventions    | Following a four week run in patients randomised to either Hypoallergenic, milk-free, lactose and sucrose-free, complete elemental formula with free AA (Neocate) or placebo (patients pre existing formulae) for six weeks. This was followed by a wash out period of six weeks and then crossed over to the other intervention for six weeks  
| Outcomes         | AD severity was assessed using SCORAD before and after each phase  
| Notes            | PP  
|                  | Four drop outs: two drank less than daily milk requirement, one refused to drink Neocate and one was discontinued due to too mild AD  

**Risk of bias**

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

### Lever 1998

| Methods                      | Scotland. Single centre. RCT  
|------------------------------|-------------------------------|
|------------------------------| parallel group AC: unclear  
|                              | RS: unclear  
|                              | B: Outcome assessor  
|                              | randomised controlled trial. Method of randomisation and concealment of allocation unclear  
| Participants                 | Setting: outpatients. Young children (n=62), with sensitivity to eggs.  
|                              | Evaluable: (n=55)  
|                              | Age: 11 to 17 months all with positive IgE blood antibodies to egg, only seven of which had a history suggestive of egg allergy.  
|                              | SAE: unclear  
|                              | Dig: as per dermatologist  
|                              | Co-T: mild to moderate topical steroids  
| Interventions                | a: General advice re AE and specific advice dietary advice vs b. general advice on AE and no dietary advice.  
|                              | Duration four weeks  
| Outcomes                     | Eczema severity assessed by extent in % terms and a composite severity score in 16 body sites  

*Dietary exclusions for established atopic eczema (Review)*

Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lever 1998  (Continued)

Notes
Randomisation done by same dietician who was giving the intervention
PP  
a: 4 withdrawals (2 defaulted and 2 incomplete records)
b: 3 withdrawals (1 defaulted, 2 incomplete records)
Co-treatment use not reported.

Risk of bias
<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

Mabin 1995

Methods
UK, Single centre. RCT D:parallel AC:unclear RS: random no tables B: outcome assessors

Participants
Setting: outpatients.
Unselected children (n=85)
Evaluable: (n=46) Age 0.3 to 13.3 yrs
SAE: atopic eczema that persisted despite conventional treatment and >12% of body surface area.
Dig: Hanifin and Rajka
Co-T: unclear

Interventions
a: normal diet (n=26) b: few foods with whey hydrolysate formula (n=27) c: few foods diet with casein hydrolysate formula (n=32) for 6 weeks

Outcomes
Clinical assessment consisted of the estimation of the body surface area affected by using charts that divided the body into 32 separate zones. Skin severity for each of the 32 zones was assessed by the extent of area affected and degree of erythema on an arbitrary scale of 0 to 3. Overall skin severity score with a possible range of 0 to 300 was achieved by summarising all 32 zones

Notes
PP 40 lost to FU, a: n=4 b: n=18 c: n=17

Risk of bias
<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

Munkvad 1984

Methods
Denmark, Single centre. RCT D:parallel AC: unclear RS: unclear B: participant, clinician, outcome assessor

Participants
Setting: hospitalised.
Unselected adults (n=33)
Evaluable: (n=25) Age 16-52 yrs
SAE: severe, atopic eczema covering >10% of body
Dig: Hanifin and Rajika
Co-T: emollients, topical steroid, antihistamines.

Interventions: Elemental diet (amino acids, essential fatty acids, glucose, trace elements, sorbic acid and vitamins) vs blended diluted diet of foodstuffs consumed by hospital inpatients. Diet for three weeks.

Outcomes: Various unpublished extent and intensity signs scored. A score between -3 and +3 was given to the degree of change for each of the clinical symptoms (erythema, infiltration and size of area involved). In addition, photographs before and after, patient itch and sleep, and various serum markers of inflammation. In evaluation the mean value of these four figures was multiplied by 100 and named 'major activity score'. An 'major activity' score of >100 was defined as the criterion for a positive response to treatment.

Notes: Eight lost to FU- (24%) mostly due to dislike of diet. Small study of intervention that is unpalatable, impractical and requires hospitalisation and dietetic input.

Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

Neild 1986

Methods: UK. Single centre. RCT. D: cross-over AC: unclear RS: unclear B: participant and outcome assessor

Participants: Setting: outpatients. Unselected children and adults (n=53), (29 female and 24 male)
Evaluable: (n=40)
Age 1-23 yrs
SAE: mild, moderate and severe.
Dig: active atopic eczema
Co-T: usual treatment

Interventions: Three six-week periods; during first and third periods, patients placed on egg and cows' milk exclusion diet and randomised to either soya or a milk containing egg and cows' milk

Outcomes: Participants reported on itch and sleep loss, use of co-treatments, composite score of area and intensity

Notes: Thirteen lost to FU. Twelve patients excluded from analysis due to non compliance as diet too difficult to adhere to. One participant developed GI symptoms followed by itch and exacerbation of eczema.

Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors' judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

Dietary exclusions for established atopic eczema (Review)
### Niggemann 2001

<table>
<thead>
<tr>
<th>Methods</th>
<th>Finland, Multicentre. RCT D: parallel AC: unclear RS: unclear B: none</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Setting: outpatients. Infants (n=73) Aged between 1 and 10 months SAE: Dig: Sampson and Seymour modified from Hanifin and Rajka with atopic and cows’ milk intolerance, proven by DBPFC Co-T?:</td>
</tr>
<tr>
<td>Interventions</td>
<td>Amino acid based formulae (AA) group (n=31) vs eHF (n=42) for six months</td>
</tr>
<tr>
<td>Outcomes</td>
<td>FU at three and six months. Clinical symptoms of AD according to SCORAD index to assess disease severity. Dietary intake measured using three-day dietary record</td>
</tr>
<tr>
<td>Notes</td>
<td>No mention of ITT analysis or withdrawals. SCORAD results for two groups was not reported separately and no table of results. Data extracted from graph. Mean SCORAD was reduced significantly in all infants at three months and six months</td>
</tr>
</tbody>
</table>

### Risk of bias

<table>
<thead>
<tr>
<th>Item</th>
<th>Authors’ judgement</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment?</td>
<td>Unclear</td>
<td>B - Unclear</td>
</tr>
</tbody>
</table>

AA: amino acid formula  
AC: methods of allocation concealment  
AE: atopic eczema  
B: blinding (participant clinician outcome assessment)  
Co-T: co treatments  
D: design  
DBPFC: double-blind, placebo-controlled food-challenge  
Diag: diagnostic criteria  
eHF: extensively hydrolysed whey formula  
FU: follow-up  
ITT: intention to treat  
PP: per protocol  
RAST: radio-allergosorbent test  
RS: method of generating randomisation sequence  
SAE: severity of atopic eczema
### Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isolauri 2000</td>
<td>Breast fed infants weaned onto eHF vs eHF plus Bifidobacterium lactic Bb-12 vs eHF plus Lactobacillus strain GG. This study was about probiotics rather than exclusion diets</td>
</tr>
<tr>
<td>Kirjavainen 2003</td>
<td>This study compared extensively hydrolysed whey formula vs the same formula supplemented with viable Lactobacillus GG or heat-inactivated Lactobacillus GG. Although the groups excluded cows milk this study was about oral supplementation of viable and heat-inactivated probiotic bacteria in the management of atopic disease</td>
</tr>
<tr>
<td>Majamaa 1997</td>
<td>This study aimed to evaluate effect of cow's milk elimination with and without the addition of Lactobacillus GG in eHF formula in infants. This study did not fit our inclusion criteria for types of studies</td>
</tr>
</tbody>
</table>

eHF - extensively hydrolysed whey formula
### Comparison 1. Dried soya vs dried egg and cows milk

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 activity score at one month</td>
<td>1</td>
<td></td>
<td>conditional OR (Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
</tbody>
</table>

### Comparison 2. eHF vs Amino acid formula

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Severity of atopic eczema at 2-3 months</td>
<td>2</td>
<td></td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Subtotals only</td>
</tr>
<tr>
<td>1.1 Infants</td>
<td>2</td>
<td>118</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
</tr>
<tr>
<td>2 Severity of atopic eczema at 6-8 months</td>
<td>2</td>
<td></td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Subtotals only</td>
</tr>
<tr>
<td>2.1 Infants</td>
<td>2</td>
<td>118</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>1.06 [-1.67, 3.80]</td>
</tr>
</tbody>
</table>

### Comparison 3. Egg exclusion vs normal diet

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Number of participants whose body surface are improved</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>1.1 Children</td>
<td>1</td>
<td></td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Not estimable</td>
</tr>
<tr>
<td>2 Change in body surface area at 6 weeks</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>2.1 Children</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
</tr>
<tr>
<td>3 Change in severity score - end of treatment</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
</tr>
<tr>
<td>3.1 Children</td>
<td>1</td>
<td></td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
</tr>
</tbody>
</table>
### Comparison 4. Few foods with whey vs normal diet

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Change in day time itch at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>1.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>2 Change in sleep disturbances at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>2.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>3 Change in body surface area affected at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>3.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>4 Change in skin severity score at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>4.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
</tbody>
</table>

### Comparison 5. Few foods with casein vs normal diet

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Change in day time itch at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>1.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>2 Change in sleep disturbances at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>2.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>3 Change in body surface area affected at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>3.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>4 Change in skin severity score at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>4.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
</tbody>
</table>

### Comparison 6. Few foods with whey vs few foods with casein

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Change in day time itch at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>1.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>2 Change in sleep disturbances at 6 weeks</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>2.1 Children</td>
<td>1</td>
<td>Mean Difference (IV, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
</tbody>
</table>
2.1 Children

3 Mean Difference (IV, Random, 95% CI) Not estimable
3 Change in body surface area affected at 6 weeks

3.1 Children

4 Mean Difference (IV, Random, 95% CI) Totals not selected
4 Change in skin severity score at 6 weeks

4.1 Children

Comparison 7. Elemental diet vs normal diet

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Number of participants whose eczema improved (change in intensity and extension) at 3 weeks</td>
<td>1</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>1.1 Children</td>
<td>1</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>2 Numbers who improved for pruritus, sleeplessness and antihistamine consumption at 3 weeks</td>
<td>1</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Totals not selected</td>
<td></td>
</tr>
<tr>
<td>2.1 Adults</td>
<td>1</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>Not estimable</td>
<td></td>
</tr>
</tbody>
</table>

Analysis 1.1. Comparison 1 Dried soya vs dried egg and cows milk, Outcome 1 activity score at one month.

Review: Dietary exclusions for established atopic eczema
Comparison: 1 Dried soya vs dried egg and cows milk
Outcome: 1 activity score at one month

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>log [conditional OR] (SE)</th>
<th>conditional OR IV(Random,95% CI)</th>
<th>conditional OR IV(Random,95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atherton, 1978</td>
<td>2.3536 (0.7827)</td>
<td></td>
<td>10.52 [2.27, 48.80]</td>
</tr>
</tbody>
</table>
**Analysis 2.1. Comparison 2 eHF vs Amino acid formula, Outcome 1 Severity of atopic eczema at 2-3 months.**

**Review:** Dietary exclusions for established atopic eczema

**Comparison:** 2 eHF vs Amino acid formula

**Outcome:** 1 Severity of atopic eczema at 2-3 months

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>eHF</th>
<th>AA formula</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>Infants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolauri 1995</td>
<td>22</td>
<td>9 (5.98)</td>
<td>23</td>
<td>9 (12.23)</td>
<td>76.1 %</td>
</tr>
<tr>
<td>Niggemann 2001</td>
<td>42</td>
<td>12 (26)</td>
<td>31</td>
<td>12 (17.4)</td>
<td>23.9 %</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>64</td>
<td>54</td>
<td>100.0 %</td>
<td>0.0 [ -4.87, 4.87 ]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.0; Chi² = 0.0, df = 1 (P = 1.00); I² =0.0%

Test for overall effect: Z = 0.0 (P = 1.0)

---

**Analysis 2.2. Comparison 2 eHF vs Amino acid formula, Outcome 2 Severity of atopic eczema at 6-8 months.**

**Review:** Dietary exclusions for established atopic eczema

**Comparison:** 2 eHF vs Amino acid formula

**Outcome:** 2 Severity of atopic eczema at 6-8 months

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>eHF</th>
<th>AA formula</th>
<th>Mean Difference</th>
<th>Weight</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>Infants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Isolauri 1995</td>
<td>22</td>
<td>5 (4.79)</td>
<td>23</td>
<td>4 (4.89)</td>
<td>93.7 %</td>
</tr>
<tr>
<td>Niggemann 2001</td>
<td>42</td>
<td>12 (28)</td>
<td>31</td>
<td>10 (19.5)</td>
<td>63 %</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>64</td>
<td>54</td>
<td>100.0 %</td>
<td>1.06 [ -1.67, 3.80 ]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.0; Chi² = 0.03, df = 1 (P = 0.86); I² =0.0%

Test for overall effect: Z = 0.76 (P = 0.45)
### Analysis 3.1. Comparison 3 Egg exclusion vs normal diet, Outcome 1 Number of participants whose body surface are improved.

**Review:** Dietary exclusions for established atopic eczema  
**Comparison:** 3 Egg exclusion vs normal diet  
**Outcome:** 1 Number of participants whose body surface are improved

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Egg exclusion</th>
<th>Normal diet</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lever 1998</td>
<td>25/28</td>
<td>16/27</td>
<td>1.51 [1.07, 2.11]</td>
<td>0.5</td>
</tr>
</tbody>
</table>

Favours usual diet  
Favours exclusion

### Analysis 3.2. Comparison 3 Egg exclusion vs normal diet, Outcome 2 Change in body surface area at 6 weeks.

**Review:** Dietary exclusions for established atopic eczema  
**Comparison:** 3 Egg exclusion vs normal diet  
**Outcome:** 2 Change in body surface area at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Egg exclusion</th>
<th>Normal diet</th>
<th>Mean Difference M-V, Random, 95% CI</th>
<th>Mean Difference M-V, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N Mean(SD)</td>
<td>N Mean(SD)</td>
<td>IV, Random, 95% CI</td>
<td>IV, Random, 95% CI</td>
</tr>
<tr>
<td>1 Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lever 1998</td>
<td>28 8.7 (10.3)</td>
<td>27 3.2 (9.8)</td>
<td>5.50 [0.19, 10.81]</td>
<td></td>
</tr>
</tbody>
</table>

Favours normal diet  
Favours egg exclusion
### Analysis 3.3. Comparison 3 Egg exclusion vs normal diet, Outcome 3 Change in severity score - end of treatment.

- **Review:** Dietary exclusions for established atopic eczema
- **Comparison:** Egg exclusion vs normal diet
- **Outcome:** Change in severity score - end of treatment

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Egg exclusion</th>
<th>Normal diet</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N  Mean(SD)</td>
<td>N  Mean(SD)</td>
<td>IV,Random,95% CI</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>1 Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lever 1998</td>
<td>28 9.4 (12.3)</td>
<td>27 3.3 (10.5)</td>
<td>-6.10 [ 0.06, 12.14 ]</td>
<td></td>
</tr>
</tbody>
</table>

### Analysis 4.1. Comparison 4 Few foods with whey vs normal diet, Outcome 1 Change in day time itch at 6 weeks.

- **Review:** Dietary exclusions for established atopic eczema
- **Comparison:** Few foods with whey vs normal diet
- **Outcome:** Change in day time itch at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods with whey</th>
<th>Normal diet</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N  Mean(SD)</td>
<td>N  Mean(SD)</td>
<td>IV,Random,95% CI</td>
<td>IV,Random,95% CI</td>
</tr>
<tr>
<td>1 Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mabin 1995</td>
<td>8  -0.1 (2.98)</td>
<td>15 0 (0.94)</td>
<td>-0.10 [-2.22, 2.02 ]</td>
<td></td>
</tr>
</tbody>
</table>
### Analysis 4.2. Comparison 4 Few foods with whey vs normal diet, Outcome 2 Change in sleep disturbances at 6 weeks.

**Review:** Dietary exclusions for established atopic eczema  
**Comparison:** Few foods with whey vs normal diet  
**Outcome:** Change in sleep disturbances at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods with whey</th>
<th>Normal diet</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Children</td>
<td>7</td>
<td>-0.4 (2.95)</td>
<td>16</td>
<td>-0.1 (0.69)</td>
</tr>
</tbody>
</table>

### Analysis 4.3. Comparison 4 Few foods with whey vs normal diet, Outcome 3 Change in body surface area affected at 6 weeks.

**Review:** Dietary exclusions for established atopic eczema  
**Comparison:** Few foods with whey vs normal diet  
**Outcome:** Change in body surface area affected at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods and whey</th>
<th>Normal diet</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Children</td>
<td>9</td>
<td>-17.8 (25.5)</td>
<td>22</td>
<td>-4.9 (18.2)</td>
</tr>
</tbody>
</table>
Analysis 4.4. Comparison 4 Few foods with whey vs normal diet, Outcome 4 Change in skin severity score at 6 weeks.

Review: Dietary exclusions for established atopic eczema

Comparison: 4 Few foods with whey vs normal diet

Outcome: 4 Change in skin severity score at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods with whey</th>
<th>Normal diet</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Children</td>
<td>9</td>
<td>-21.8 (30.18)</td>
<td>22</td>
<td>-15.9 (30.36)</td>
</tr>
</tbody>
</table>

Analysis 5.1. Comparison 5 Few foods with casein vs normal diet, Outcome 1 Change in day time itch at 6 weeks.

Review: Dietary exclusions for established atopic eczema

Comparison: 5 Few foods with casein vs normal diet

Outcome: 1 Change in day time itch at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods and casein</th>
<th>Normal diet</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Children</td>
<td>14</td>
<td>-0.6 (1.37)</td>
<td>15</td>
<td>0 (0.94)</td>
</tr>
</tbody>
</table>
Analysis 5.2. Comparison 5 Few foods with casein vs normal diet, Outcome 2 Change in sleep disturbances at 6 weeks.

Review: Dietary exclusions for established atopic eczema

Comparison: 5 Few foods with casein vs normal diet

Outcome: 2 Change in sleep disturbances at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods with casein</th>
<th>Normal diet</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>1 Children</td>
<td>14</td>
<td>-0.2 (1.39)</td>
<td>16</td>
<td>-0.1 (0.69)</td>
</tr>
</tbody>
</table>

Analysis 5.3. Comparison 5 Few foods with casein vs normal diet, Outcome 3 Change in body surface area affected at 6 weeks.

Review: Dietary exclusions for established atopic eczema

Comparison: 5 Few foods with casein vs normal diet

Outcome: 3 Change in body surface area affected at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods and casein</th>
<th>Normal diet</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>1 Children</td>
<td>15</td>
<td>-5 (34)</td>
<td>22</td>
<td>-4.9 (18.2)</td>
</tr>
</tbody>
</table>
Analysis 5.4. Comparison 5 Few foods with casein vs normal diet, Outcome 4 Change in skin severity score at 6 weeks.

Review: Dietary exclusions for established atopic eczema
Comparison: 5 Few foods with casein vs normal diet
Outcome: 4 Change in skin severity score at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods and casein</th>
<th>Normal diet</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Children</td>
<td>15</td>
<td>-13.5 (42.67)</td>
<td>22</td>
<td>-15.9 (30.36)</td>
</tr>
</tbody>
</table>

Analysis 6.1. Comparison 6 Few foods with whey vs few foods with casein, Outcome 1 Change in day time itch at 6 weeks.

Review: Dietary exclusions for established atopic eczema
Comparison: 6 Few foods with whey vs few foods with casein
Outcome: 1 Change in day time itch at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods with whey</th>
<th>Few foods and casein</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Children</td>
<td>8</td>
<td>-0.1 (2.98)</td>
<td>14</td>
<td>-0.6 (1.37)</td>
</tr>
</tbody>
</table>
### Analysis 6.2. Comparison 6 Few foods with whey vs few foods with casein, Outcome 2 Change in sleep disturbances at 6 weeks.

**Review:** Dietary exclusions for established atopic eczema  
**Comparison:** 6 Few foods with whey vs few foods with casein  
**Outcome:** 2 Change in sleep disturbances at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods and whey</th>
<th>Few foods and casein</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Children</td>
<td>7</td>
<td>-0.4 (2.95)</td>
<td>14</td>
<td>-0.2 (1.39)</td>
</tr>
</tbody>
</table>

### Analysis 6.3. Comparison 6 Few foods with whey vs few foods with casein, Outcome 3 Change in body surface area affected at 6 weeks.

**Review:** Dietary exclusions for established atopic eczema  
**Comparison:** 6 Few foods with whey vs few foods with casein  
**Outcome:** 3 Change in body surface area affected at 6 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Few foods with whey</th>
<th>Few foods and casein</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>Mean(SD)</td>
<td>N</td>
<td>Mean(SD)</td>
</tr>
<tr>
<td>Children</td>
<td>9</td>
<td>-17.8 (25.5)</td>
<td>15</td>
<td>-5 (34)</td>
</tr>
</tbody>
</table>
Analysis 6.4. Comparison 6 Few foods with whey vs few foods with casein, Outcome 4 Change in skin severity score at 6 weeks.

Review: Dietary exclusions for established atopic eczema

Comparison: 6 Few foods with whey vs few foods with casein

Outcome: 4 Change in skin severity score at 6 weeks

Study or subgroup | Few foods whey | Few foods casein | Mean Difference | Mean Difference
N | Mean(SD) | N | Mean(SD) | IV,Random,95% CI | IV,Random,95% CI

1 Children
Mabin 1995
9 -21.8 (30.36) 15 -13.5 (42.67) -8.30 [-37.62, 21.02]

Analysis 7.1. Comparison 7 Elemental diet vs normal diet, Outcome 1 Number of participants whose eczema improved (change in intensity and extension) at 3 weeks.

Review: Dietary exclusions for established atopic eczema

Comparison: 7 Elemental diet vs normal diet

Outcome: 1 Number of participants whose eczema improved (change in intensity and extension) at 3 weeks

Study or subgroup | Elemental diet | Normal diet | Risk Ratio M-H,Random,95% CI | Risk Ratio M-H,Random,95% CI
n/N | n/N |

1 Children
Munkvad 1984
5/16 4/9
0.70 [0.25, 1.97]
Analysis 7.2. Comparison 7 Elemental diet vs normal diet, Outcome 2 Numbers who improved for pruritus, sleeplessness and antihistamine consumption at 3 weeks.

Review: Dietary exclusions for established atopic eczema
Comparison: 7 Elemental diet vs normal diet
Outcome: 2 Numbers who improved for pruritus, sleeplessness and antihistamine consumption at 3 weeks

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Elemental diet</th>
<th>Normal diet</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n/N</td>
<td>n/N</td>
<td>M-H, Random, 95% CI</td>
<td>M-H, Random, 95% CI</td>
</tr>
<tr>
<td>Adults</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Munkvad 1984</td>
<td>3/16</td>
<td>1/9</td>
<td>1.69 [0.20, 13.93]</td>
<td></td>
</tr>
</tbody>
</table>

Favours normal diet Favours elemental

A D D I T I O N A L  T A B L E S

Table 1. Terms used to categorise trial participants with atopic eczema (AE)

<table>
<thead>
<tr>
<th>Definite AE</th>
<th>Possible AE</th>
<th>Not AE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atopic eczema</td>
<td>Periorbital eczema</td>
<td>Seborrheic eczema</td>
</tr>
<tr>
<td>Atopic dermatitis</td>
<td>Childhood eczema</td>
<td>Contact eczema</td>
</tr>
<tr>
<td>Besnier’s prurigo</td>
<td>Infantile eczema</td>
<td>Allergic contact eczema</td>
</tr>
<tr>
<td>Neurodermatitis atopica (German)</td>
<td>'Eczema' unspecified</td>
<td>Irritant contact eczema</td>
</tr>
<tr>
<td>Flexural eczema/dermatitis</td>
<td>Constitutional eczema</td>
<td>Discoid/nummular eczema</td>
</tr>
<tr>
<td></td>
<td>Endogenous eczema</td>
<td>Asteatotic eczema</td>
</tr>
<tr>
<td></td>
<td>Chronic eczema</td>
<td>Varicose/stasis eczema</td>
</tr>
<tr>
<td></td>
<td>Neurodermatitis</td>
<td>Photo-/light-sensitive eczema</td>
</tr>
<tr>
<td></td>
<td>Neurodermatitis (German)</td>
<td>Chronic actinic dermatitis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dishydrotic eczema</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pompholyx eczema</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hand eczema</td>
</tr>
</tbody>
</table>
Table 1. Terms used to categorise trial participants with atopic eczema (AE)  

<table>
<thead>
<tr>
<th>Frictional lichenoid dermatitis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lichen simplex</td>
</tr>
<tr>
<td>Occupational dermatitis</td>
</tr>
<tr>
<td>Prurigo</td>
</tr>
</tbody>
</table>

Table 2. Quality components

<table>
<thead>
<tr>
<th>Study</th>
<th>Allocation generation</th>
<th>Allocation concealment</th>
<th>Masking</th>
<th>Loss to FU</th>
<th>Included in analysis</th>
<th>Certainty of AD</th>
<th>Baseline comparability</th>
<th>Compliance</th>
<th>Severity of AD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atherton 1978</td>
<td>unclear</td>
<td>unclear</td>
<td>participants and outcome assessors</td>
<td>16</td>
<td>n=20 (56%)</td>
<td>clinically typical AD</td>
<td>unclear</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Cant 1986</td>
<td>random number table</td>
<td>unclear</td>
<td>unclear</td>
<td>2</td>
<td>17(87%)</td>
<td>criteria by Yates</td>
<td>unclear</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Isolauri 1995</td>
<td>unclear</td>
<td>unclear</td>
<td>unclear</td>
<td>-</td>
<td>100%</td>
<td>Hanifin</td>
<td>unclear</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Leung 2004</td>
<td>unclear</td>
<td>unclear</td>
<td>outcome assessor</td>
<td>4</td>
<td>73.3%</td>
<td>Hanifin</td>
<td>unclear</td>
<td>clear</td>
<td>unclear</td>
</tr>
<tr>
<td>Lever 1998</td>
<td>unclear</td>
<td>unclear</td>
<td>outcome assessor</td>
<td>7</td>
<td>89%</td>
<td>unclear</td>
<td>no</td>
<td>unclear</td>
<td>unclear</td>
</tr>
<tr>
<td>Mabin 1995</td>
<td>random number tables</td>
<td>unclear</td>
<td>outcome assessor</td>
<td>39</td>
<td>54%</td>
<td>Hanifin</td>
<td>Yes</td>
<td>clear</td>
<td>unclear</td>
</tr>
<tr>
<td>Munkvad 1984</td>
<td>unclear</td>
<td>unclear</td>
<td>participant, clinician, outcome assessor</td>
<td>8</td>
<td>76%</td>
<td>Hanifin</td>
<td>unclear</td>
<td>clear</td>
<td>severe</td>
</tr>
<tr>
<td>Neild 1986</td>
<td>unclear</td>
<td>unclear</td>
<td>participant and outcome assessor</td>
<td>13</td>
<td>75%</td>
<td>unclear</td>
<td>unclear</td>
<td>clear</td>
<td>unclear</td>
</tr>
</tbody>
</table>
Table 2. Quality components (Continued)

<table>
<thead>
<tr>
<th>Niggemann 2001</th>
<th>unclear</th>
<th>unclear</th>
<th>none</th>
<th>unclear</th>
<th>All</th>
<th>Hanifin</th>
<th>NS diff</th>
<th>unclear</th>
<th>unclear</th>
</tr>
</thead>
</table>

**APPENDICES**

Appendix 1. CENTRAL (CLIB issue 1,2005) search strategy

Search Strategy

#1 (atopic next dermatitis) or (atopic next eczema) or neurodermatitis in All Fields, from 1800 to 2005 in all products
#2 (infantile next eczema) or (childhood next eczema) or (benign next prurigo) in All Fields in all products
#3 MeSH descriptor Dermatitis, Atopic explode all trees in MeSH products
#4 MeSH descriptor Neurodermatitis explode all trees in MeSH products
#5 (child near nutrition) or (adolescent near nutrition) or (infant near nutrition) or (bottle near feeding) or (breast near feeding) or weaning in All Fields, from 1800 to 2005 in all products
#6 (dietary near protein*) or (egg near protein*) or (milk near protein*) or (vegetable near protein*) in All Fields, from 1800 to 2005 in all products
#7 ((food or egg or milk or nut or peanut or wheat) near hypersensitivity) in All Fields, from 1800 to 2005 in all products
#8 elimination or exclusion in All Fields in all products
#9 elemental diet in All Fields in all products
#10 MeSH descriptor Adolescent Nutrition explode all trees in MeSH products
#11 MeSH descriptor Infant Nutrition explode all trees in MeSH products
#12 MeSH descriptor Child Nutrition explode all trees in MeSH products
#13 MeSH descriptor Bottle Feeding explode all trees in MeSH products
#14 MeSH descriptor Breast Feeding explode all trees in MeSH products
#15 MeSH descriptor Weaning explode all trees in MeSH products
#16 MeSH descriptor Dietary Proteins explode all trees in MeSH products
#17 MeSH descriptor Egg Proteins, Dietary explode all trees in MeSH products
#18 MeSH descriptor Milk Proteins explode all trees in MeSH products
#19 MeSH descriptor Vegetable Proteins explode all trees in MeSH products
#20 MeSH descriptor Food Hypersensitivity explode all trees in MeSH products
#21 MeSH descriptor Foods, Specialized explode all trees in MeSH products
#22 (#1 OR #2 OR #3 OR #4) #23 (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21) #24 (#22 AND #23)
## Appendix 2. MEDLINE search strategy

<table>
<thead>
<tr>
<th>Search Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. RANDOMIZED CONTROLLED TRIAL.pt.</td>
</tr>
<tr>
<td>2. CONTROLLED CLINICAL TRIAL.pt.</td>
</tr>
<tr>
<td>3. RANDOMIZED CONTROLLED TRIALS.sh.</td>
</tr>
<tr>
<td>4. RANDOM ALLOCATION.sh.</td>
</tr>
<tr>
<td>5. DOUBLE BLIND METHOD.sh.</td>
</tr>
<tr>
<td>6. SINGLE-BLIND METHOD.sh.</td>
</tr>
<tr>
<td>7. or/1-6</td>
</tr>
<tr>
<td>8. animal/ not human/</td>
</tr>
<tr>
<td>9. 7 not 8</td>
</tr>
<tr>
<td>10. CLINICAL TRIAL.pt.</td>
</tr>
<tr>
<td>11. exp CLINICAL TRIALS/</td>
</tr>
<tr>
<td>13. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.</td>
</tr>
<tr>
<td>14. PLACEBOS.sh.</td>
</tr>
<tr>
<td>15. placebo$.ti,ab.</td>
</tr>
<tr>
<td>16. random$.ti,ab.</td>
</tr>
<tr>
<td>17. RESEARCH DESIGN.sh.</td>
</tr>
<tr>
<td>18. ot/10-17</td>
</tr>
<tr>
<td>19. 18 not 8</td>
</tr>
<tr>
<td>20. 19 not 9</td>
</tr>
<tr>
<td>21. COMPARATIVE STUDY.sh.</td>
</tr>
<tr>
<td>22. exp EVALUATION STUDIES/</td>
</tr>
<tr>
<td>23. FOLLOW UP STUDIES.sh.</td>
</tr>
<tr>
<td>24. PROSPECTIVE STUDIES.sh.</td>
</tr>
<tr>
<td>25. (control$ or prospectiv$ or volunteer$).ti,ab.</td>
</tr>
<tr>
<td>26. ot/21-25</td>
</tr>
<tr>
<td>27. 26 not 8</td>
</tr>
<tr>
<td>28. 27 not (9 or 20)</td>
</tr>
<tr>
<td>29. 9 or 20 or 28</td>
</tr>
<tr>
<td>30. exp Dermatitis, Atopic/</td>
</tr>
<tr>
<td>31. dermatitis, atopic.mp.</td>
</tr>
<tr>
<td>32. eczema, atopic.mp. or exp Dermatitis, Atopic/</td>
</tr>
<tr>
<td>33. atopic dermatitis.mp.</td>
</tr>
<tr>
<td>34. atopic eczema.mp.</td>
</tr>
<tr>
<td>35. infantile eczema.mp.</td>
</tr>
<tr>
<td>36. childhood eczema.mp.</td>
</tr>
<tr>
<td>37. exp CHILD/</td>
</tr>
<tr>
<td>38. exp INFANT/</td>
</tr>
<tr>
<td>39. neurodermatitis.mp. or exp NEURODERMATITIS/</td>
</tr>
<tr>
<td>40. besniers prurigo.mp.</td>
</tr>
<tr>
<td>41. 30 or 31 or 32 or 33 or 34</td>
</tr>
<tr>
<td>42. 37 and 41</td>
</tr>
<tr>
<td>43. 38 and 41</td>
</tr>
<tr>
<td>44. 35 or 36 or 39 or 40</td>
</tr>
<tr>
<td>45. 41 or 42 or 43 or 44</td>
</tr>
<tr>
<td>46. child nutrition.mp. or exp Child Nutrition/</td>
</tr>
<tr>
<td>47. adolescent nutrition.mp. or exp Adolescent Nutrition/</td>
</tr>
</tbody>
</table>
Appendix 3. EMBASE search strategy

Search Strategy

1. random$.mp. 2. factorial$.mp.
3. crossover$.mp.
4. placebo$.mp. or PLACEBO/
5. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]
6. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, drug trade name, original title, device manufacturer, drug manufacturer name]
7. assign$.mp.
8. volunteer$.mp. or VOLUNTEER/
9. Crossover Procedure/
10. Double Blind Procedure/
11. Randomized Controlled Trial/
12. Single Blind Procedure/
13. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
14. atopic dermatitis.mp. or exp Atopic Dermatitis/
15. atopic eczema.mp.
16. infantile eczema.mp.
17. childhood eczema.mp.
18. Child/
19. Infant/
20. neurodermatitis.mp. or exp NEURODERMATITIS/
21. besnier's prurigo.mp.
22. 14 or 15
23. 18 and 22
24. 19 and 22
25. 16 or 17 or 23 or 24 or 20 or 21 or 22
26. child nutrition.mp. or exp Child Nutrition/
27. adolescent nutrition.mp.
28. infant nutrition.mp. or exp Infant Nutrition/
29. bottle feeding.mp. or exp Bottle Feeding/
30. breast feeding.mp. or exp Breast Feeding/
31. weaning.mp. or exp WEANING/
32. dietary proteins.mp.
33. milk proteins.mp. or exp Milk Protein/
34. egg proteins.mp. or exp Egg Protein/
35. vegetable proteins.mp. or exp Vegetable Protein/
36. egg hypersensitivity.mp.
37. milk hypersensitivity.mp.
38. exp Food Allergy/
39. nut hypersensitivity.mp.
40. peanut hypersensitivity.mp.
41. wheat hypersensitivity.mp.
42. elimination.mp.
43. exclusion.mp.
44. elemental diet.mp. or exp Elemental Diet/
45. foods, specialized.mp.
46. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 40 or 41 or 42 or 43 or 44
47. 13 and 25 and 46

Appendix 4. PsycINFO search strategy

Search Strategy

1. exp Dermatitis/ or atopic dermatitis.mp.2. exp Eczema/ or atopic eczema.mp.
3. exp NEURODERMATITIS/ or neurodermatitis.mp.
4. childhood eczema.mp.
5. 1 or 2 or 3 or 4
6. diet.mp. or exp DIETS/
7. food allergy.mp. or exp Food Allergies/
8. dietary exclusions.mp.
9. egg exclusion.mp.
10. diet$ manipulation$ .mp.
11. 6 or 7 or 8 or 9 or 10
12. randomized controlled trial.pt.
13. clinical trial.mp. or exp Clinical Trials/
14. 12 or 13
15. 5 and 11 and 14
## Search Strategy

1. randomized controlled trial$ /
2. random allocation /
3. double blind method /
4. single blind method.mp.
5. exp Clinical trials /
6. (clin$ adj25 trial$).mp. [mp=abstract, heading words, title]
7. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$ or dummy)).mp. [mp=abstract, heading words, title]
8. (placebo$ or random$).mp. [mp=abstract, heading words, title]
9. research design/ or clinical trials/ or comparative study/ or double blind method/ or random allocation/
10. prospective studies.mp.
11. cross over studies.mp.
12. Follow up studies /
13. control$.mp.
14. (multicent$ or multi-cent$).mp. [mp=abstract, heading words, title]
15. ((stud or design$) adj25 (factorial or prospective or intervention or crossover or cross-over or quasi-experiment$)).mp. [mp=abstract, heading words, title]
16. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17. exp Dermatitis, Atopic /
18. dermatitis, atopic.mp.
19. eczema, atopic.mp. or exp Dermatitis, Atopic /
20. atopic dermatitis.mp.
21. atopic eczema.mp.
22. infantile eczema.mp.
23. childhood eczema.mp.
24. exp CHILD /
25. exp INFANT /
26. neurodermatitis.mp. or exp NEURODERMATITIS /
27. besniers prurigo.mp.
28. 17 or 18 or 19 or 20 or 21
29. 24 and 28
30. 25 and 28
31. 22 or 23 or 26 or 27
32. 28 or 29 or 30 or 31
33. child nutrition.mp. or exp Child Nutrition /
34. adolescent nutrition.mp. or exp Adolescent Nutrition /
35. infant nutrition.mp. or exp Infant Nutrition /
36. bottle feeding.mp. or exp Bottle Feeding /
37. breast feeding.mp. or exp Breast Feeding /
38. exp WEANING/ or weaning.mp.
39. dietary proteins.mp. or exp Dietary Proteins /
40. egg proteins.mp. or exp Egg Proteins /
41. milk proteins.mp. or exp Milk Proteins /
42. vegetable proteins.mp. or exp Vegetable Proteins /
43. food hypersensitivity.mp. or exp Food Hypersensitivity /
44. nut hypersensitivity.mp. or exp Nut Hypersensitivity /
45. peanut hypersensitivity.mp. or exp Peanut Hypersensitivity /
46. wheat hypersensitivity.mp. or exp Wheat Hypersensitivity/
47. exp FOOD HYPERSENSITIVITY/
48. foods, specialized.mp. or exp Foods, Specialized/
49. (diet$ and (elimination or exclusion)).mp. [mp=abstract, heading words, title]
50. 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 48 or 49
51. 16 and 32 and 50

**WHAT'S NEW**

Last assessed as up-to-date: 5 November 2007.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>22 May 2008</td>
<td>Amended</td>
<td>Converted to new review format.</td>
</tr>
</tbody>
</table>

**HISTORY**

Protocol first published: Issue 2, 2005
Review first published: Issue 1, 2008

**CONTRIBUTIONS OF AUTHORS**

Link with editorial base and co-ordinate contributions from co-authors (FB-H)
Draft protocol (FB-H, FD)
Consumer - input to draft protocol (RH)
Run search (FD and FB-H)
Identify relevant titles and abstracts from searches (FB-H, FD)
Obtain copies of trials (FB-H)
Selection of trials (FB-H, FD)
Extract data from trials (FB-H, FD)
Enter data into revman (FB-H)
Carry out analysis (FB-H)
Write up of full review (FB-H)
Interpret data (FB-H, FD, HW)
DECLARATIONS OF INTEREST
None known

SOURCES OF SUPPORT

Internal sources
• University of Nottingham, School of Nursing, UK.
• University of Nottingham, Cochrane Skin Group, CEBD., UK.

External sources
• No sources of support supplied

INDEX TERMS

Medical Subject Headings (MeSH)
Dermatitis, Atopic [*diet therapy]; Egg Hypersensitivity [diet therapy]; Food, Formulated; Milk Hypersensitivity [diet therapy]; Randomized Controlled Trials as Topic

MeSH check words
Humans